| Antibodies based treatment against COVID-19 |
| 1. |
H-IG |
Octapharm and Takeda Pharmaceutical Co. |
Pre-clinical |
The Phase 1 trials will begin in end of the spring |
(https://phrma.org/coronavirus)
(https://www..com/articles/drugmaker-takeda-is-working-on-coronavirus-drug-11583301660?mod=article_inlinewsj)
(https://pink.pharmaintelligence.informa.com/PS141926/US-FDA-To-Exercise-Maximum-Regulatory-Flexibility-For-COVID19-PlasmaDerived-Therapeutics) |
| 2. |
VIR-7831 and VIR-7832 |
GSK/Vir Biotech/Samsung |
Pre-clinical |
The Phase 2 trials will begin in the month of july and september |
(https://investors.vir.bio/news-releases/news-release-details/gsk-and-vir-biotechnology-enter-collaboration-find-coronavirus) |
| 3. |
Thymosin; PD-1 blocking antibody |
Numerous trials with Chinese research sponsors |
Clinical |
The Phase 2 of clinical trial will end on April 30, 2020 |
(https://www.com/article/304658biocentury) |
| 4. |
Gimsilumab, |
Roivant Sciences |
Clinical |
The phase 2 Study begins from April 2020 |
(https://roivant.com/roivant-announces-development-of-anti-gm-csf-monoclonal-antibody-to-prevent-and-treat-acute-respiratory-distress-syndrome-ards-in-patients-with-covid-19/) |
| 5. |
Siltuximab |
EUSA Pharma |
Clinical |
Interim of April 2020 |
(https://www.com/news/eusa-pharma-and-the-papa-giovanni-xxiii-hospital/eusapharma) |
| 6. |
SAB-185 |
SAb Biotherapeutics |
Pre-clinical |
Phase 1 starts early summer 2020 |
(https://sabbiotherapeutics.com/2020/04/13/hhs-facilitates-development-of-immunotherapies-for-covid-19-patients/) |
| 7. |
Soliris |
Alexion |
Clinical |
The phase 2 Study begins from April 2020 |
(https://ir.alexion.com/news-releases/news-release-details/alexion-statement-solirisr-eculizumab-and-covid-19) |
| 8. |
rCIG |
GigaGen |
Pre-clinical |
– |
(https://.com/biotech/gigagen-jumps-into-covid-19-arena-polyclonal-antibodies?mkt_tok=eyJpIjoiT0dFNE16bGhPRFk1WTJNMiIsInQiOiJiUDhYM1ZWdzJLY04zbnc1T3IzVmFUK2NVVzFSeXY3SFhtZnNVWU5wWHFSYUxjcVwva0ZLZUVGRTBVSlBoMFlpY1FHQ0ZGODF0akV6TENzb3pWSmR0bFwvRllHbnQ5amptalwvZTdhN0J5UlJMeXVhSnhYcHNabkNBVXhhZTFSVHNJRHVtVEpqcU02aXN3SWRFSXRuUGNkVlE9PSJ9&mrkid=72869502) |
| 9 |
Ilaris |
Novartis |
Clinical |
– |
(https://www.com/article/health-coronavirus-novartis/novartis-ceo-malaria-drug-is-biggest-hope-against-coronavirus-sonntagszeitung-idUSL8N2BM02Wreuters) |
| 10. |
Ultomiris |
Alexion Pharmaceuticals |
Clinical |
The phase 2 will be begin in the month of May 2020 |
(https://www..com/news/home/20200420005221/en/Alexion-Announces-Plans-Initiate-Phase-3-Studybusinesswire) |
| 11. |
COVID-EIG |
Emergent BioSolutions |
Pre-clinical |
The phase 2 will be begin in the month of August 2020 |
(https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-initiates-development-plasma-derived?field_nir_news_date_value%5bmin%5d =) |
| 12. |
Octagam |
Octapharma |
Clinical |
– |
(https://www.com/news/home/20200416005144/en/New-COVID-19-Clinical-Trial-Supported-Octapharma-USAbusinesswire) |
| Cell based therapies used against COVID-19 |
| 1 |
Mesenchymal stem cells |
Numerous trials with global research sponsors |
Clinical |
– |
(https://www..com/article/304658biocentury) |
| 2. |
Autologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs) |
Celltex |
– |
– |
(https://www.com/article/releases/celltex-autologous-stem-cell-case-study-published-by-gavin-publishers-demonstrates-potential-cure-for-rheumatoid-arthritis/?keywords=Autologous+Adipose-Tissue+Derived+Mesenchymal+Stem+Cells+(ADMSCsbiospace)
|
| 3. |
Ryoncil |
Mesoblast |
Pre-clinical |
– |
(https://.com/research/melatonin-stem-cells-researchers-step-up-unconventional-approaches-to-covid-19?mkt_tok=eyJpIjoiTlRKak1UZzROV1l5TWpnMSIsInQiOiJ6K0xXSlwvcFZhcmpWenhOS1pxOExUTnlsdzlPM080bVRiQ2phcG1mQmowQWQ2S24yZXZ2alBqVHNJaVUzZGRNQjM5aFQySkg4cEFvdUZrQ0lBWmluTkl1a3NVK3dFUEFRTTUwSkhEMnIwTHR1QUt4VEs4ZGsrc1pZZWF6bWdNTEZ2YXRsc2RlT0haMGV6VWE1bkNVUHB3PT0ifQ%3D%3D&mrkid=72869502) |
| 4. |
MultiStem, bone marrow stem cells |
Athersys/The University of Texas Health Science Center at Houston |
Clinical |
Phase 2/3 trial to start 2Q 2020 |
(https://www.com/article/barda-says-athersys-cell-therapy-highly-relevant-for-covid-19/biospace)
(https://www.com/news/home/20200413005160/en/FDA-Authorizes-Athersys-Initiate-Pivotal-Clinical-Trialbusinesswire) |
| 5 |
Allogeneic T-cell therapies |
Baylor College of Medicine/AlloVir |
Pre-clinical |
– |
(https://clinicaltrials.gov/ct2/show/NCT04338347?type=Expn&cond=COVID-19&draw=2) |
| 6 |
CYNK-001, allogeneic, natural killer cell therapy |
Celularity |
Clinical |
The phase 1/2 will be begin |
(https://www.com/news-releases/celularity-announces-fda-clearance-of-ind-application-for-cynk-001-in-coronavirus-first-in-cellular-therapy-301034141.htmlprnewswire) |
| 7 |
CAP-1002, allogenic cardiosphere-derived cell |
Capricor Inc. |
– |
– |
(http://www.irdirect.net/prviewer/release/id/4280782) |
| 8 |
haNK, natural killer cells |
ImmunityBio/NantKwest |
Pre-clinical |
– |
(https://www.com/news/home/20200414005353/en/NantKwest-ImmunityBio-Announce-Therapeutics-Vaccines-Combatting-COVID-19businesswire) |
| RNA based treatment for COVID-19 |
| 1. |
RNAi - testing 150 RNAis |
Sirnaomics |
Pre-clinical |
– |
(https://www..org/sections/health-shots/2020/02/19/807338329/hunt-for-new-coronavirus-treatments-includes-gene-silencing-and-monoclonal-antibnpr) |
| 2. |
siRNA candidates |
Alnylam Pharmaceuticals/Vir Biotech |
Pre-clinical |
– |
(https://www.com/news/home/20200402005167/en/Vir-Alnylam-Expand-Collaboration-Advance-Investigational-RNAibusinesswire) |
| 3. |
Ampligen; (rintatolimod) |
AIM ImmunoTech/National Institute of Infectious Diseases in Japan |
Pre-clinical |
– |
(https://finance.yahoo.com/news/aim-immunotech-drug-ampligen-tested-103000673.html) |
| 4. |
OT-101, a TGF-Beta antisense drug candidate |
Mateon Therapeutics |
Clinical |
– |
(https://www.com/analysis/coronavirus-mers-cov-drugs/clinicaltrialsarena) |
| 5. |
Inhaled mRNA |
Neurimmune/Ethris |
Pre-clinical |
Phase 1 to start Q4 2020 |
(https://www.neurimmune.com/news/neurimmune-and-ethris-sign-collaboration-agreement-to-rapidly-develop-inhaled-mrna-based-antibody-therapy-for-the-treatment-of-covid-19) |
